Ingramon, a Peptide Inhibitor of MCP-1 Chemokine, Reduces Migration of Blood Monocytes Stimulated by Glioma-Conditioned Medium
- Authors: Krasnikova T.L.1, Arefieva T.I.1, Pylaeva E.A.1, Sidorova M.V.1
-
Affiliations:
- Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
- Issue: Vol 160, No 4 (2016)
- Pages: 480-482
- Section: Oncology
- URL: https://journals.rcsi.science/0007-4888/article/view/236744
- DOI: https://doi.org/10.1007/s10517-016-3201-0
- ID: 236744
Cite item
Abstract
Malignant gliomas are most common and fatal primary brain tumors. In addition to neoplastic cells, the tumor tissue contains microglial cells and monocyte-derived macrophages. It is an established fact that monocyte recruiting promotes the tumor growth and dissemination. Monocyte chemotactic protein-1 (MCP-1) is the major attractant for monocytes. We have previously synthesized an MCP-1 antagonist ingramon, a synthetic peptide fragment (65–76) of this chemokine. In the present study, we demonstrated that glioma-conditioned medium contains MCP-1 and stimulates migration of blood monocytes. Ingramon inhibited the effect of glioma-conditioned medium on monocyte migration.
About the authors
T. L. Krasnikova
Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
Author for correspondence.
Email: tlkrasnikova@gmail.com
Russian Federation, Moscow
T. I. Arefieva
Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
Email: tlkrasnikova@gmail.com
Russian Federation, Moscow
E. A. Pylaeva
Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
Email: tlkrasnikova@gmail.com
Russian Federation, Moscow
M. V. Sidorova
Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
Email: tlkrasnikova@gmail.com
Russian Federation, Moscow